> top > docs > PMC:7402624 > spans > 39188-41269 > annotations

PMC:7402624 / 39188-41269 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T360 36-40 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T361 297-302 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T362 304-307 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T363 450-454 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T364 521-524 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T365 536-541 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T366 603-606 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T367 622-626 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T368 804-806 Body_part denotes PB http://purl.org/sig/ont/fma/fma84371
T369 855-860 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T370 927-935 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T371 1286-1288 Body_part denotes PB http://purl.org/sig/ont/fma/fma84371
T372 1364-1366 Body_part denotes PB http://purl.org/sig/ont/fma/fma84371
T373 1447-1450 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T374 1461-1466 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T375 1643-1646 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T376 1657-1662 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T377 1823-1825 Body_part denotes PB http://purl.org/sig/ont/fma/fma84371
T378 1881-1885 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T379 1992-1996 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1421 283-286 Gene denotes CD4 Gene:920
1422 291-294 Gene denotes CD8 Gene:925
1423 311-315 Gene denotes CD38 Gene:952
1424 509-512 Gene denotes CD4 Gene:920
1425 517-520 Gene denotes CD8 Gene:925
1426 528-532 Gene denotes CD38 Gene:952
1427 610-614 Gene denotes CD38 Gene:952
1428 616-619 Gene denotes CD4 Gene:920
1429 841-844 Gene denotes CD4 Gene:920
1430 1442-1446 Gene denotes CD38 Gene:952
1431 1455-1458 Gene denotes CD8 Gene:925
1432 1638-1642 Gene denotes CD38 Gene:952
1433 1651-1654 Gene denotes CD8 Gene:925
1434 849-852 Gene denotes CD8 Gene:925
1435 1261-1269 Species denotes patients Tax:9606
1436 1339-1347 Species denotes patients Tax:9606
1437 1414-1422 Species denotes patients Tax:9606
1438 1603-1611 Species denotes patients Tax:9606
1439 1784-1792 Species denotes patients Tax:9606
1440 2018-2026 Species denotes patients Tax:9606
1441 917-926 Species denotes SARS-CoV2 Tax:2697049
1442 722-726 Chemical denotes cTfh
1443 1107-1117 Chemical denotes Remdesivir MESH:C000606551
1444 1122-1125 Chemical denotes HCQ MESH:D006886
1445 1286-1288 Chemical denotes PB
1446 1364-1366 Chemical denotes PB
1447 1544-1556 Chemical denotes nitric oxide MESH:D009569
1448 1719-1731 Chemical denotes nitric oxide MESH:D009569
1449 1743-1750 Chemical denotes steroid MESH:D013256
1450 82-90 Disease denotes COVID-19 MESH:C000657245
1451 470-481 Disease denotes lymphopenia MESH:D008231
1452 653-678 Disease denotes coagulation complications MESH:D001778
1453 752-764 Disease denotes co-infection MESH:D060085
1454 1303-1317 Disease denotes hyperlipidemia MESH:D006949
1455 2009-2017 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T306 82-90 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T307 470-481 Disease denotes lymphopenia http://purl.obolibrary.org/obo/MONDO_0003783
T308 755-764 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T309 804-806 Disease denotes PB http://purl.obolibrary.org/obo/MONDO_0019035
T310 917-921 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T311 1286-1288 Disease denotes PB http://purl.obolibrary.org/obo/MONDO_0019035
T312 1303-1317 Disease denotes hyperlipidemia http://purl.obolibrary.org/obo/MONDO_0021187
T313 1364-1366 Disease denotes PB http://purl.obolibrary.org/obo/MONDO_0019035
T314 1823-1825 Disease denotes PB http://purl.obolibrary.org/obo/MONDO_0019035
T315 2009-2017 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T660 34-40 http://purl.obolibrary.org/obo/CL_0000236 denotes B cell
T661 283-286 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T662 291-294 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T663 295-302 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T664 311-315 http://purl.obolibrary.org/obo/PR_000001408 denotes CD38
T665 328-337 http://purl.obolibrary.org/obo/CLO_0001658 denotes activated
T666 425-426 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T667 448-454 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T668 455-465 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T669 509-512 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T670 517-520 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T671 528-532 http://purl.obolibrary.org/obo/PR_000001408 denotes CD38
T672 534-541 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T673 610-614 http://purl.obolibrary.org/obo/PR_000001408 denotes CD38
T674 616-619 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T675 620-626 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T676 712-721 http://purl.obolibrary.org/obo/CLO_0001658 denotes activated
T677 841-844 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T678 849-852 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T679 853-860 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T680 1442-1446 http://purl.obolibrary.org/obo/PR_000001408 denotes CD38
T681 1455-1458 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T682 1459-1466 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T683 1638-1642 http://purl.obolibrary.org/obo/PR_000001408 denotes CD38
T684 1651-1654 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T685 1655-1662 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T686 1879-1885 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T687 1990-1996 http://purl.obolibrary.org/obo/CL_0000236 denotes B cell

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T272 308-310 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T273 525-527 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T274 607-609 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T275 804-806 Chemical denotes PB http://purl.obolibrary.org/obo/CHEBI_53319|http://purl.obolibrary.org/obo/CHEBI_60686
T277 1053-1062 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T278 1286-1288 Chemical denotes PB http://purl.obolibrary.org/obo/CHEBI_53319|http://purl.obolibrary.org/obo/CHEBI_60686
T280 1364-1366 Chemical denotes PB http://purl.obolibrary.org/obo/CHEBI_53319|http://purl.obolibrary.org/obo/CHEBI_60686
T282 1451-1453 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T283 1544-1556 Chemical denotes nitric oxide http://purl.obolibrary.org/obo/CHEBI_16480
T284 1551-1556 Chemical denotes oxide http://purl.obolibrary.org/obo/CHEBI_25741|http://purl.obolibrary.org/obo/CHEBI_29356
T286 1647-1649 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T287 1719-1731 Chemical denotes nitric oxide http://purl.obolibrary.org/obo/CHEBI_16480
T288 1726-1731 Chemical denotes oxide http://purl.obolibrary.org/obo/CHEBI_25741|http://purl.obolibrary.org/obo/CHEBI_29356
T290 1743-1750 Chemical denotes steroid http://purl.obolibrary.org/obo/CHEBI_35341
T291 1823-1825 Chemical denotes PB http://purl.obolibrary.org/obo/CHEBI_53319|http://purl.obolibrary.org/obo/CHEBI_60686

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T85 448-465 http://purl.obolibrary.org/obo/GO_0042110 denotes T cell activation
T86 450-465 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T87 653-664 http://purl.obolibrary.org/obo/GO_0050817 denotes coagulation
T88 1063-1078 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T11 470-481 Phenotype denotes lymphopenia http://purl.obolibrary.org/obo/HP_0001888
T12 1303-1317 Phenotype denotes hyperlipidemia http://purl.obolibrary.org/obo/HP_0003077

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T226 0-192 Sentence denotes We next asked whether these T and B cell dynamics related to clinical measures of COVID-19 disease, by correlating changes in immune features from D0 to D7 with clinical information (Fig. 5G).
T227 193-239 Sentence denotes These analyses revealed distinct correlations.
T228 240-482 Sentence denotes Decreases in all populations of responding CD4 and CD8 T cells (HLA-DR+CD38+, KI67+, or activated cTfh) between D0 and D7 were positively correlated with PMN and WBC counts, suggesting a relationship between T cell activation and lymphopenia.
T229 483-586 Sentence denotes Furthermore, decreases in CD4 and CD8 HLA-DR+CD38+ T cells positively correlated with APACHE III score.
T230 587-692 Sentence denotes However, stable HLA-DR+CD38+ CD4 T cell responses correlated with coagulation complications and ferritin.
T231 693-807 Sentence denotes Whereas decreasing activated cTfh over time was related to co-infection, the opposite pattern was observed for PB.
T232 808-1089 Sentence denotes Increases in proliferating KI67+ CD4 and CD8 T cells over time were positively correlated to increasing anti-SARS-CoV2 antibody from day 0 to day 7, suggesting that some individuals might have been hospitalized during the expansion phase of the antiviral immune response (Fig. 5G).
T233 1090-1193 Sentence denotes Finally, neither Remdesivir nor HCQ treatment correlated with any of these immune features in Fig. 5G).
T234 1194-1409 Sentence denotes Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D).
T235 1410-1674 Sentence denotes All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medication or inhaled nitric oxide whereas these treatments were less common for patients with stable or increasing CD38+HLA-DR+ CD8 T cells (fig. S6E).
T236 1675-1837 Sentence denotes In contrast, vasoactive medication, inhaled nitric oxide, and early steroid treatment were equally common in patients with increasing or decreasing PB (fig. S6D).
T237 1838-1945 Sentence denotes Similar patterns were apparent for other T cell populations and these categorical clinical data (fig. S6F).
T238 1946-2081 Sentence denotes Thus, the trajectory of change in the T and B cell response in COVID-19 patients was strongly connected to clinical metrics of disease.